Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Comment by smallcaploveron Feb 04, 2013 7:28am
168 Views
Post# 20932555

RE: I'd like to see a merger

RE: I'd like to see a merger

Interesting product but I don't see the ned benefit to VIV in a merger of the two.  Kane's product probably doesn't have a whole lot of IP behind it, and their distribution is probably no better than that for VIV - nascent.  Avivagen is taking its time getting other distribution agreements signed which is frustrating, but I understand that it's an ongoing process...  they have a lot to deliver on in the near-term and I'm hopeful they do.  They're probably better off on their own - a merger is a huge distraction.

Hank's press release was a nice recap of last year, but pretty thin on detail in terms of what's to come.  It would be nice if they'd take the risk and put something meaningful in print and then stick to it.  No more soft press releases.  Attendance numbers at Woofstock is hardly going to get this story/stock moving...

Bullboard Posts